DGAT2 and metabolic dysfunction-associated steatotic liver disease: DGAT2, which is abundantly expressed in the liver, primarily uses fatty acids from the DNL pathway to synthesize TG (Parlati et al., 2021), and researchers (Gluchowski et al., 2019) found that Dgat2 deletion downregulated hepatic expression of DNL-related genes and significantly reduced hepatic TAG levels (by 70%) in NAFLD mice.